Other ongoing trials (NCT01713972, NCT01902173) are also assessing dual MEK/BRAF inhibition in patients with BRAF‐mutant cholangiocarcinoma and shall help elucidate the role of this strategy in these patients. This evidence concerns the gene BRAF and cholangiocarcinoma.